Jian-qin Zhao1, Jie Shao, Wen-wei Zhong. 1. Pediatric Department, Ruijin Hospital Affiliated to Shanghai Second Medical University, Shanghai (200025). lele750216@163.com
Abstract
OBJECTIVE: To evaluate the efficacy and safety of chuankezhi injection to children with bronchial asthma. METHODS:Sixty-eight children suffered from asthma and/or asthma complicated with allergic rhinitis were randomly divided into the treated group and the control group, who received treatment of chuankezhi injection and Ginkgo injection respectively. Clinical observation on daily-symptom scores, and lung functions as peak expiratory flow (PEF), and forced expiratory volume in one second (FEV1) were conducted. RESULTS: After treatment the median of symptomatic scores in the treated group was 6.0 (M25-M75: 4.9-21.5) and that in the control group was 10.0 (M25-M75: 6.19-27.5), showing significant difference between groups; significant improvement was shown in the treated group, in which the PEF variance rate was reduced to 4.3 +/- 5.1%, while in the control group, it was 5.9 +/- 6.7%, the difference between the two groups was significant. Similar result also showed in comparison of FEV1 rate. CONCLUSION:Chuankezhi is helpful in improving clinical symptoms, reducing PEF variance rate and enhancing lung function in children with bronchial asthma, so as to be benefit to the long-term stable alleviation of asthma.
RCT Entities:
OBJECTIVE: To evaluate the efficacy and safety of chuankezhi injection to children with bronchial asthma. METHODS: Sixty-eight children suffered from asthma and/or asthma complicated with allergic rhinitis were randomly divided into the treated group and the control group, who received treatment of chuankezhi injection and Ginkgo injection respectively. Clinical observation on daily-symptom scores, and lung functions as peak expiratory flow (PEF), and forced expiratory volume in one second (FEV1) were conducted. RESULTS: After treatment the median of symptomatic scores in the treated group was 6.0 (M25-M75: 4.9-21.5) and that in the control group was 10.0 (M25-M75: 6.19-27.5), showing significant difference between groups; significant improvement was shown in the treated group, in which the PEF variance rate was reduced to 4.3 +/- 5.1%, while in the control group, it was 5.9 +/- 6.7%, the difference between the two groups was significant. Similar result also showed in comparison of FEV1 rate. CONCLUSION: Chuankezhi is helpful in improving clinical symptoms, reducing PEF variance rate and enhancing lung function in children with bronchial asthma, so as to be benefit to the long-term stable alleviation of asthma.